Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487318 · ClinicalTrials.gov registry record · Phase 2
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
A Phase 2 study of Chronic Hepatitis C, sponsored by Bader, Ted, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00487318 is a Phase 2 study of Chronic Hepatitis C that has completed, run by Bader, Ted, M.D.. The registered enrollment target is 40 participants, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00487318, a Phase 2 study of Chronic Hepatitis C, has completed, sponsored by Bader, Ted, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
Conditions Studied
Interventions
- DRUG standard of care
- DRUG fluvastatin
Study Locations (1)
Oklahoma
- Veterans Administration Medical Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487318
The ClinicalTrials.gov registry entry for NCT00487318 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower). The listed sponsor is Bader, Ted, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which standard of care is the first listed.
NCT00487318 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00487318 about?
NCT00487318 is a clinical study titled "Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin". Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for...
What is the current status of trial NCT00487318?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-06. Estimated completion is 2010-10.
What conditions does trial NCT00487318 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT00487318?
The interventions under investigation include: standard of care (DRUG), fluvastatin (DRUG).
Who is sponsoring clinical trial NCT00487318?
This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00487318 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
-
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
COMPLETED · Phase 2
-
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
COMPLETED · Phase 2
-
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
COMPLETED · Phase 2
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.